Top

Published in:

Open Access 01-12-2023 | Polymerase Chain Reaction | Research

Relationship between clinical features and droplet digital PCR copy number in non-HIV patients with pneumocystis pneumonia

Authors: Wenjie Bian, Yu Xie, Ying Shang, Lili Zhao, Zhengwu Yang, Xinqian Ma, Yukun He, Wenyi Yu, Wen Xi, Donghong Yang, Fang Wang, Yanwen Chen, Pihua Gong, Zhancheng Gao

Published in: BMC Infectious Diseases | Issue 1/2023

Abstract

Objective

Droplet digital PCR (ddPCR) is a novel assay to detect pneumocystis jjrovecii (Pj) which has been defined to be more sensitive than qPCR in recent studies. We aimed to explore whether clinical features of pneumocystis pneumonia (PCP) were associated with ddPCR copy numbers of Pj.

Methods

A total of 48 PCP patients were retrospectively included. Pj detection was implemented by ddPCR assay within 4 h. Bronchoalveolar fluid (BALF) samples were collected from 48 patients with molecular diagnosis as PCP via metagenomic next generation sequencing (mNGS) or quantitative PCR detection. Univariate and multivariate logistic regression were performed to screen out possible indicators for the severity of PCP. The patients were divided into two groups according to ddPCR copy numbers, and their clinical features were further analyzed.

Results

Pj loading was a pro rata increase with serum (1,3)-beta-D glucan, D-dimmer, neutrophil percentage, procalcitonin and BALF polymorphonuclear leucocyte percentage, while negative correlation with albumin, PaO2/FiO2, BALF cell count, and BALF lymphocyte percentage. D-dimmer and ddPCR copy number of Pj were independent indicators for moderate/severe PCP patients with PaO2/FiO2 lower than 300. We made a ROC analysis of ddPCR copy number of Pj for PaO2/FiO2 index and grouped the patients according to the cut-off value (2.75). The high copy numbers group was characterized by higher level of inflammatory markers. Compared to low copy number group, there was lower level of the total cell count while higher level of polymorphonuclear leucocyte percentage in BALF in the high copy numbers group. Different from patients with high copy numbers, those with high copy numbers had a tendency to develop more severe complications and required advanced respiratory support.

Conclusion

The scenarios of patients infected with high ddPCR copy numbers of Pj showed more adverse clinical conditions. Pj loading could reflect the severity of PCP to some extent.

Fortea JI, Cuadrado A, Puente Á, Álvarez Fernández P, Huelin P, Álvarez Tato C, et al. Is routine Prophylaxis Against Pneumocystis jirovecii needed in liver transplantation? A retrospective single-centre experience and current prophylaxis strategies in Spain. J Clin Med. 2020;9(11). https://doi.org/10.3390/jcm9113573.

Liu CJ, Lee TF, Ruan SY, Yu CJ, Chien JY, Hsueh PR. Clinical characteristics, treatment outcomes, and prognostic factors of Pneumocystis pneumonia in non-HIV-infected patients. Infect Drug Resist. 2019;12:1457–67. https://doi.org/10.2147/idr.S199761.CrossRefPubMedPubMedCentral

Lee WS, Hsueh PR, Hsieh TC, Chen FL, Ou TY, Jean SS. Caspofungin salvage therapy in Pneumocystis jirovecii pneumonia. J Microbiol Immunol Infect. 2017;50(4):547–8. https://doi.org/10.1016/j.jmii.2016.03.008.CrossRefPubMed

Brakemeier S, Pfau A, Zukunft B, Budde K, Nickel P. Prophylaxis and treatment of Pneumocystis Jirovecii pneumonia after solid organ transplantation. Pharmacol Res. 2018;134:61–7. https://doi.org/10.1016/j.phrs.2018.06.010.CrossRefPubMed

Kim TO, Lee JK, Kwon YS, Kim YI, Lim SC, Kim MS, et al. Clinical characteristics and prognosis of patients with pneumocystis jirovecii pneumonia without a compromised illness. PLoS ONE. 2021;16(2):e0246296. https://doi.org/10.1371/journal.pone.0246296.CrossRefPubMedPubMedCentral

Enomoto T, Azuma A, Kohno A, Kaneko K, Saito H, Kametaka M, et al. Differences in the clinical characteristics of Pneumocystis jirovecii pneumonia in immunocompromized patients with and without HIV infection. Respirology. 2010;15(1):126–31. https://doi.org/10.1111/j.1440-1843.2009.01660.x.CrossRefPubMed

Salsé M, Mercier V, Carles MJ, Lechiche C, Sasso M. Performance of the RealStar(®) pneumocystis jirovecii PCR kit for the diagnosis of Pneumocystis pneumonia. Mycoses. 2021;64(10):1230–7. https://doi.org/10.1111/myc.13354.CrossRefPubMed

Hammarström H, Grankvist A, Broman I, Kondori N, Wennerås C, Gisslen M, et al. Serum-based diagnosis of Pneumocystis pneumonia by detection of Pneumocystis jirovecii DNA and 1,3-β-D-glucan in HIV-infected patients: a retrospective case control study. BMC Infect Dis. 2019;19(1):658. https://doi.org/10.1186/s12879-019-4289-4.CrossRefPubMedPubMedCentral

Del Corpo O, Butler-Laporte G, Sheppard DC, Cheng MP, McDonald EG, Lee TC. Diagnostic accuracy of serum (1–3)-β-D-glucan for Pneumocystis jirovecii pneumonia: a systematic review and meta-analysis. Clin Microbiol Infect. 2020;26(9):1137–43. https://doi.org/10.1016/j.cmi.2020.05.024.CrossRefPubMed

10.

Duan J, Gao J, Liu Q, Sun M, Liu Y, Tan Y, et al. Characteristics and prognostic factors of Non-HIV immunocompromised patients with Pneumocystis Pneumonia diagnosed by Metagenomics Next-Generation sequencing. Front Med (Lausanne). 2022;9:812698. https://doi.org/10.3389/fmed.2022.812698.CrossRefPubMed

11.

Goldberg B, Sichtig H, Geyer C, Ledeboer N, Weinstock GM. Making the Leap from Research Laboratory to Clinic: Challenges and Opportunities for Next-Generation sequencing in Infectious Disease Diagnostics. mBio. 2015;6(6):e01888–15. https://doi.org/10.1128/mBio.01888-15.CrossRefPubMedPubMedCentral

12.

Gaňová M, Zhang H, Zhu H, Korabečná M, Neužil P. Multiplexed digital polymerase chain reaction as a powerful diagnostic tool. Biosens Bioelectron. 2021;181:113155. https://doi.org/10.1016/j.bios.2021.113155.CrossRefPubMed

13.

Kojabad AA, Farzanehpour M, Galeh HEG, Dorostkar R, Jafarpour A, Bolandian M, et al. Droplet digital PCR of viral DNA/RNA, current progress, challenges, and future perspectives. J Med Virol. 2021;93(7):4182–97. https://doi.org/10.1002/jmv.26846.CrossRefPubMedPubMedCentral

14.

Yi J, Wang N, Wu J, Tang Y, Zhang J, Zhu L, et al. Development of a Droplet Digital polymerase chain reaction for sensitive detection of Pneumocystis jirovecii in respiratory tract specimens. Front Med (Lausanne). 2021;8:761788. https://doi.org/10.3389/fmed.2021.761788.CrossRefPubMed

15.

Li H, Bai R, Zhao Z, Tao L, Ma M, Ji Z, et al. Application of droplet digital PCR to detect the pathogens of infectious diseases. Biosci Rep. 2018;38(6). https://doi.org/10.1042/bsr20181170.

16.

Chen B, Xie Y, Zhang N, Li W, Liu C, Li D, et al. Evaluation of Droplet Digital PCR assay for the diagnosis of Candidemia in blood samples. Front Microbiol. 2021;12:700008. https://doi.org/10.3389/fmicb.2021.700008.CrossRefPubMedPubMedCentral

17.

Zheng Y, Jin J, Shao Z, Liu J, Zhang R, Sun R, et al. Development and clinical validation of a droplet digital PCR assay for detecting Acinetobacter baumannii and Klebsiella pneumoniae in patients with suspected bloodstream infections. Microbiologyopen. 2021;10(6):e1247. https://doi.org/10.1002/mbo3.1247.CrossRefPubMedPubMedCentral

18.

Jitmuang A, Nititammaluk A, Boonsong T, Sarasombath PT, Sompradeekul S, Chayakulkeeree M. A novel droplet digital polymerase chain reaction for diagnosis of Pneumocystis pneumonia (PCP)-a clinical performance study and survey of sulfamethoxazole-trimethoprim resistant mutations. J Infect. 2021;83(6):701–8. https://doi.org/10.1016/j.jinf.2021.09.014.CrossRefPubMed

19.

Wu Y, Wang F, Wang C, Tang X, Liu X, Li S, et al. Detection of Pneumocystis jirovecii and Toxoplasma gondii in patients with lung infections by a duplex qPCR assay. PLoS Negl Trop Dis. 2021;15(12):e0010025. https://doi.org/10.1371/journal.pntd.0010025.CrossRefPubMedPubMedCentral

20.

Liu L, Yuan M, Shi Y, Su X. Clinical performance of BAL Metagenomic Next-Generation sequence and serum (1,3)-β-D-Glucan for Differential diagnosis of Pneumocystis jirovecii Pneumonia and Pneumocystis jirovecii Colonisation. Front Cell Infect Microbiol. 2021;11:784236. https://doi.org/10.3389/fcimb.2021.784236.CrossRefPubMedPubMedCentral

21.

Bordon J, Aliberti S, Fernandez-Botran R, Uriarte SM, Rane MJ, Duvvuri P, et al. Understanding the roles of cytokines and neutrophil activity and neutrophil apoptosis in the protective versus deleterious inflammatory response in pneumonia. Int J Infect Dis. 2013;17(2):e76–83. https://doi.org/10.1016/j.ijid.2012.06.006.CrossRefPubMed

22.

Giulia B, Luisa A, Concetta S, Bruna LS, Chiara B, Marcello C. Procalcitonin and community-acquired pneumonia (CAP) in children. Clin Chim Acta. 2015;451(Pt B):215–8. https://doi.org/10.1016/j.cca.2015.09.031.CrossRefPubMed

23.

Huang X, Li D, Liu F, Zhao D, Zhu Y, Tang H. Clinical significance of D-dimer levels in refractory Mycoplasma pneumoniae pneumonia. BMC Infect Dis. 2021;21(1):14. https://doi.org/10.1186/s12879-020-05700-5.CrossRefPubMedPubMedCentral

24.

Zou XL, Feng DY, Wu WB, Yang HL, Zhang TT. Blood urea nitrogen to serum albumin ratio independently predicts 30-day mortality and severity in patients with Escherichia coli bacteraemia. Med Clin (Barc). 2021;157(5):219–25. https://doi.org/10.1016/j.medcli.2020.06.060.CrossRefPubMed

25.

Watanabe T, Yasuoka A, Tanuma J, Yazaki H, Honda H, Tsukada K, et al. Serum (1–>3) beta-D-glucan as a noninvasive adjunct marker for the diagnosis of Pneumocystis pneumonia in patients with AIDS. Clin Infect Dis. 2009;49(7):1128–31. https://doi.org/10.1086/605579.CrossRefPubMed

26.

Mercier T, Aissaoui N, Gits-Muselli M, Hamane S, Prattes J, Kessler HH, et al. Variable correlation between Bronchoalveolar Lavage Fluid Fungal load and Serum-(1,3)-β-d-Glucan in patients with Pneumocystosis-A Multicenter ECMM Excellence Center Study. J Fungi (Basel). 2020;6(4). https://doi.org/10.3390/jof6040327.

27.

Szvalb AD, Malek AE, Jiang Y, Bhatti MM, Wurster S, Kontoyiannis DP. Serum (1,3)-Beta-d-Glucan has suboptimal performance for the diagnosis of Pneumocystis jirovecii pneumonia in cancer patients and correlates poorly with respiratory burden as measured by quantitative PCR. J Infect. 2020;81(3):443–51. https://doi.org/10.1016/j.jinf.2020.07.003.CrossRefPubMed

28.

Tang G, Tong S, Yuan X, Lin Q, Luo Y, Song H, et al. Using routine laboratory markers and immunological indicators for Predicting Pneumocystis jiroveci Pneumonia in Immunocompromised Patients. Front Immunol. 2021;12:652383. https://doi.org/10.3389/fimmu.2021.652383.CrossRefPubMedPubMedCentral

29.

Ewig S, Bauer T, Schneider C, Pickenhain A, Pizzulli L, Loos U, et al. Clinical characteristics and outcome of Pneumocystis carinii pneumonia in HIV-infected and otherwise immunosuppressed patients. Eur Respir J. 1995;8(9):1548–53.CrossRefPubMed

30.

Sun J, Su J, Xie Y, Yin MT, Huang Y, Xu L, et al. Plasma IL-6/IL-10 ratio and IL-8, LDH, and HBDH Level predict the severity and the risk of death in AIDS patients with Pneumocystis Pneumonia. J Immunol Res. 2016;2016:1583951. https://doi.org/10.1155/2016/1583951.CrossRefPubMedPubMedCentral

31.

Torres HA, Chemaly RF, Storey R, Aguilera EA, Nogueras GM, Safdar A, et al. Influence of type of cancer and hematopoietic stem cell transplantation on clinical presentation of Pneumocystis jiroveci pneumonia in cancer patients. Eur J Clin Microbiol Infect Dis. 2006;25(6):382–8. https://doi.org/10.1007/s10096-006-0149-4.CrossRefPubMed

Title: Relationship between clinical features and droplet digital PCR copy number in non-HIV patients with pneumocystis pneumonia
Authors: Wenjie Bian
Yu Xie
Ying Shang
Lili Zhao
Zhengwu Yang
Xinqian Ma
Yukun He
Wenyi Yu
Wen Xi
Donghong Yang
Fang Wang
Yanwen Chen
Pihua Gong
Zhancheng Gao
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Polymerase Chain Reaction
Pneumonia
Human Immunodeficiency Virus
Published in: BMC Infectious Diseases / Issue 1/2023
Electronic ISSN: 1471-2334
DOI: https://doi.org/10.1186/s12879-023-08580-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2023

Evaluate prognostic accuracy of SOFA component score for mortality among adults with sepsis by machine learning method

Reducing urinary catheter use in geriatric patients - results of a single-center champion-led intervention

COVID-19 monoclonal antibody treatment impact on symptoms and post-COVID conditions among high-risk patients at a Federally Qualified Health Center

Humoral and T cell responses to SARS-CoV-2 reveal insights into immunity during the early pandemic period in Pakistan

Causes and risk factors of death among people who inject drugs in Indonesia, Ukraine and Vietnam: findings from HPTN 074 randomized trial

A prospective patient registry to monitor safety, effectiveness, and utilisation of bedaquiline in patients with multidrug-resistant tuberculosis in South Korea

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials